Arvinas Sees Unusually High Options Volume (NASDAQ:ARVN)

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) saw unusually large options trading activity on Friday. Stock investors acquired 30,996 call options on the company. This is an increase of 617% compared to the average daily volume of 4,324 call options.

Arvinas Price Performance

NASDAQ:ARVN traded down $0.19 during mid-day trading on Friday, reaching $7.29. The stock had a trading volume of 596,125 shares, compared to its average volume of 1,437,290. Arvinas has a fifty-two week low of $5.90 and a fifty-two week high of $34.11. The business's 50 day moving average is $7.45 and its 200 day moving average is $13.04. The stock has a market cap of $531.73 million, a P/E ratio of -11.01 and a beta of 2.19.

Arvinas (NASDAQ:ARVN - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.93) by $2.07. Arvinas had a negative net margin of 10.92% and a negative return on equity of 7.74%. The company's revenue was up 646.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.97) earnings per share. Equities analysts expect that Arvinas will post -3.81 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in Arvinas by 18.4% during the first quarter. Vanguard Group Inc. now owns 8,362,200 shares of the company's stock worth $58,703,000 after buying an additional 1,299,639 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Arvinas by 6.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,103,011 shares of the company's stock worth $78,656,000 after acquiring an additional 249,295 shares during the period. RTW Investments LP grew its holdings in shares of Arvinas by 19.8% during the 4th quarter. RTW Investments LP now owns 3,334,308 shares of the company's stock worth $63,919,000 after purchasing an additional 551,979 shares in the last quarter. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Arvinas during the 4th quarter worth approximately $42,332,000. Finally, Alyeska Investment Group L.P. bought a new stake in shares of Arvinas during the first quarter valued at approximately $12,636,000. Institutional investors own 95.19% of the company's stock.

Analyst Ratings Changes

A number of research firms recently commented on ARVN. Wells Fargo & Company lowered their price objective on shares of Arvinas from $26.00 to $19.00 and set an "overweight" rating on the stock in a research note on Friday, May 2nd. Bank of America decreased their target price on Arvinas from $54.00 to $28.00 and set a "buy" rating for the company in a research note on Wednesday, March 12th. TD Cowen lowered Arvinas from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. UBS Group cut their price target on shares of Arvinas from $74.00 to $21.00 and set a "buy" rating for the company in a report on Thursday, May 15th. Finally, HC Wainwright set a $24.00 price objective on shares of Arvinas in a research note on Monday, June 2nd. Ten analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $20.29.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.